ReviewMedicina (Kaunas, Lithuania)2023
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.
Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Testosterone modulation of default mode network and its effects on cognitive function and mood in humans: a systematic review.Frontiers in neuroscience · 2026Pooled it
- Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Tinosinenside A ameliorates Alzheimer's disease-related pathology in APP/PS1 mice, accompanied by reduced neuroinflammation and altered microglial phenotype-associated marker expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cognitive Trajectories and Associated Factors in Prostate Cancer Survivors Over a 3-Year Prospective Study.Psycho-oncology · 2026Article
- Integrated Transcriptomic Analysis Identifies Potential Biomarkers in Castration-Resistant Prostate Cancer.World journal of oncology · 2026Article
- Abiraterone Acetate Affects Gene Expression Profile in a Human Male Neuronal Cell Line: Potential Mechanism for Cognitive Deficits with Prostate Cancer Therapy.Life (Basel, Switzerland) · 2026Article
- The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Apoptotic cell clearance triggers epithelial fate reprogramming during prostate regression.Cell death & disease · 2026Article
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Symptom cluster profiles and their impact on quality of life in Chinese patients with prostate cancer undergoing ADT: a cross-sectional study.Frontiers in oncology · 2026Article
- Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.Oncology research · 2026Article
- Proteome-Based Plasma Biomarkers for Cognitive Dysfunction in an Androgen Deprivation Model.Molecular neurobiology · 2025Article
- Unveiling the anticancer potential of Curcuma amada rhizome extract against prostate cancer through computational and experimental approaches.Scientific reports · 2025Article
- Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.International journal of molecular sciences · 2025Review
- Nanoparticles with curcumin and piperine modulate steroid biosynthesis in prostate cancer.Scientific reports · 2025Article
- From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008-2023).American journal of men's healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Prostate cancer is the second leading cause of cancer death in men in the United States. Androgen deprivation therapy (ADT) is currently the primary treatment for metastatic prostate cancer, and some studies have shown that the use of anti-androgen drugs is related to a reduction in cognitive function, mood changes, diminished quality of life, dementia, and possibly Alzheimer's disease. ADT has potential physiological effects such as a reduction in white matter integrity and a negative impact on hypothalamic functions due to the lowering of testosterone levels or the blockade of downstream androgen receptor signaling by first- and second-generation anti-androgen drugs. A comparative analysis of prostate cancer patients undergoing ADT and Alzheimer patients identified over 30 shared genes, illustrating common ground for the mechanistic underpinning of the symptomatology. The purpose of this review was to investigate the effects of ADT on cognitive function, mood, and quality of life, as well as to analyze the relationship between ADT and Alzheimer's disease. The evaluation of prostate cancer patient cognitive ability via neurocognitive testing is described. Future studies should further explore the connection among cognitive deficits, mood disturbances, and the physiological changes that occur when hormonal balance is altered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.